New drug combo tested for aggressive lymphoma that resists standard treatment
NCT ID NCT07480850
Summary
This study is testing whether adding a newer immunotherapy drug called glofitamab to a standard chemotherapy combination (GemOx) can help patients with diffuse large B-cell lymphoma that hasn't responded well to initial treatment. The trial will enroll 40 adults whose cancer showed signs of remaining after three cycles of first-line therapy. Researchers will measure how many patients achieve complete remission and how long the treatment keeps the cancer under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing,
Beijing, China
Conditions
Explore the condition pages connected to this study.